Implementation of Empagliflozin in Patients with Diabetes Mellitus Type 2 and Established Cardiovascular Disease: Estimation of 5-Year Survival and Costs in Sweden

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1869-6961
Extent
Online-Ressource
Language
Englisch
Notes
online resource.

Bibliographic citation
Implementation of Empagliflozin in Patients with Diabetes Mellitus Type 2 and Established Cardiovascular Disease: Estimation of 5-Year Survival and Costs in Sweden ; volume:11 ; number:12 ; day:6 ; month:10 ; year:2020 ; pages:2921-2930 ; date:12.2020
Diabetes therapy ; 11, Heft 12 (6.10.2020), 2921-2930, 12.2020

Creator
Bernfort, Lars
Husberg, Magnus
Wiréhn, Ann-Britt
Rosenqvist, Ulf
Gustavsson, Staffan
Karlsdotter, Kristina
Levin, Lars-Åke
Contributor
SpringerLink (Online service)

DOI
10.1007/s13300-020-00937-4
URN
urn:nbn:de:101:1-2020121818382051580981
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
15.08.2025, 7:33 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Bernfort, Lars
  • Husberg, Magnus
  • Wiréhn, Ann-Britt
  • Rosenqvist, Ulf
  • Gustavsson, Staffan
  • Karlsdotter, Kristina
  • Levin, Lars-Åke
  • SpringerLink (Online service)

Other Objects (12)

Empagliflozin (Diabetes mellitus Typ 2) : Addendum zum Auftrag A16-12

Empagliflozin (Diabetes mellitus Typ 2) : Addendum zum Auftrag A16-12

Empagliflozin/Metformin (Diabetes mellitus Typ 2) : Addendum zum Auftrag A16-13

Empagliflozin/Metformin (Diabetes mellitus Typ 2) : Addendum zum Auftrag A16-13

Empagliflozin/Linagliptin (Diabetes mellitus Typ 2) : Nutzenbewertung gemäß § 35a SGB V

Empagliflozin/Linagliptin (Diabetes mellitus Typ 2) : Nutzenbewertung gemäß § 35a SGB V

Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus

Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus

Disease Burden and Healthcare Costs for T2D Patients With and Without Established Cardiovascular Disease in Sweden: A Retrospective Cohort Study

Disease Burden and Healthcare Costs for T2D Patients With and Without Established Cardiovascular Disease in Sweden: A Retrospective Cohort Study

Societal costs of fetal alcohol syndrome in Sweden

Societal costs of fetal alcohol syndrome in Sweden

Governance strategy and costs: board compensation in Sweden

Governance strategy and costs: board compensation in Sweden

The societal costs of problem gambling in Sweden

The societal costs of problem gambling in Sweden

Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China

Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China

Pooled Safety and Tolerability Analysis of Empagliflozin in Patients with Type 2 Diabetes Mellitus

Pooled Safety and Tolerability Analysis of Empagliflozin in Patients with Type 2 Diabetes Mellitus

Empagliflozin (Diabetes mellitus Typ 2 bei Kindern und Jugendlichen); Nutzenbewertung gemäß § 35a SGB V : Dossierbewertung

Empagliflozin (Diabetes mellitus Typ 2 bei Kindern und Jugendlichen); Nutzenbewertung gemäß § 35a SGB V : Dossierbewertung

Effects of empagliflozin in different phases of diabetes mellitus-related cardiomyopathy: a prospective observational study

Effects of empagliflozin in different phases of diabetes mellitus-related cardiomyopathy: a prospective observational study

Related objects